Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy.
Journal of thrombosis and haemostasis : JTH 2013 Aug 11 (8): 1617-9.
Blondon M, Wiggins K L, Harrington L B, Psaty B M, Smith N
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 22, 2019
- Content source: